Search

Your search keyword '"Pozos, Tamara C."' showing total 3 results
Start Over Author "Pozos, Tamara C." Publication Year Range Last 3 years
3 results on '"Pozos, Tamara C."'

2. Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper‐IgE Syndrome: A Case Series and Literature Review.

Author

Dick, Jenna K., Boull, Christina, Pozos, Tamara C., and Maguiness, Sheilagh M.

Subjects
*ATOPIC dermatitis, *GENETIC disorders, *DISEASE relapse, *LUNG infections, *CHILD patients
Abstract

ABSTRACT Hyperimmunoglobulin E syndrome (HIES) is a group of rare genetic disorders characterized by severe atopic dermatitis and recurrent skin and pulmonary infections. The efficacy of dupilumab in pediatric patients with HIES‐associated severe atopic dermatitis is relatively understudied. Here, we present a series of three children with HIES, two with AD‐HIES caused by STAT3 mutations, and one with AR‐HIES caused by biallelic mutations in ZNF341. In all cases, dupilumab treatment led to sustained clearance of severe atopic dermatitis over multiple years, as well as improvements in systemic symptoms of HIES. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Successful Rituximab Monotherapy in Advanced-stage, Epstein-Barr Virus-positive Diffuse Large B-Cell Lymphoma in an Adolescent With Systemic Juvenile Idiopathic Arthritis

Author

Takahashi, Takuto, Hobday, Patricia M., Pozos, Tamara C., and Gordon, Peter M.

Abstract

Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) in pediatrics most commonly occurs as an iatrogenic immunodeficiency-associated lymphoproliferative disease. We report an 18-year-old female individual with refractory systemic juvenile idiopathic arthritis, treated with multiple immunosuppressive agents, who was diagnosed with stage III, EBV+ DLBCL. The patient achieved sustained complete remission after 4 weekly doses of rituximab monotherapy and reduction of immunosuppression. This case suggests that a post-transplant lymphoproliferative disease-like treatment approach can be a safe and effective therapy in a nontransplant, yet severely immunosuppressed, patient with EBV+ DLBCL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results